Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK5 | Q8IW41 | 3/20 | 0.53 |
| ▸ | PTK6 | Q13882 | 3/20 | 0.46 |
| ▸ | LCK | P06239 | 2/20 | 0.46 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.46 |
| ▸ | VNN1 | O95497 | 9/20 | 0.45 |
| ▸ | CCNK | O75909 | 3/20 | 0.41 |
| ▸ | CDK12 | Q9NYV4 | 3/20 | 0.41 |
| ▸ | CDK1 | P06493 | 2/20 | 0.39 |
| ▸ | CDK2 | P24941 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14369554 | 0.86 | MAPKAPK5 (0.55) | MAPKAPK5PTK6LCKAURKBCCNK | |
| SCHEMBL2217167 | 0.83 | MAPKAPK5 (0.56) | MAPKAPK5PTK6LCKAURKB | |
| SCHEMBL3794125 | 0.82 | MAPKAPK5 (0.57) | MAPKAPK5PTK6LCKAURKB | |
| SCHEMBL3796368 | 0.81 | MAPKAPK5 (0.55) | MAPKAPK5PTK6LCKAURKB | |
| SCHEMBL2216055 | 0.81 | MAPKAPK5 (0.62) | MAPKAPK5PTK6LCKAURKB | |
| SCHEMBL2217389 | 0.80 | MAPKAPK5 (0.59) | MAPKAPK5PTK6LCKAURKB | |
| SCHEMBL2220116 | 0.79 | MAPKAPK5 (0.60) | MAPKAPK5PTK6LCKAURKB | |
| SCHEMBL13918321 | 0.78 | MAPKAPK5 (0.56) | MAPKAPK5PTK6LCKAURKB | |
| SCHEMBL2217385 | 0.78 | MAPKAPK5 (0.68) | MAPKAPK5PTK6LCKAURKB | |
| SCHEMBL2218488 | 0.78 | MAPKAPK5 (0.56) | MAPKAPK5PTK6LCKAURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110178067-A1 | TRIAZOLOPYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | ANDREWS MARTIN JAMES INGLIS | 2011-07-21 | — | — | US | claimed |
| EP-2029602-B1 | TRIAZOLOPYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE & INFLAMMATORY DISEASES | GALAPAGOS NV (BE) | 2010-04-21 | — | — | EP | claimed |
| US-7501411-B2 | Triazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS, NV (BE) | 2009-03-10 | — | — | US | claimed |
| US-20080090818-A1 | Triazolopyrazine compounds useful for the treatment of degenerative & inflammatory diseases | GALAPAGOS NV (BE) | 2008-04-17 | — | — | US | claimed |
| US-20110178067-A1 | TRIAZOLOPYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | ANDREWS MARTIN JAMES INGLIS | 2011-07-21 | — | — | US | disclosed |
| US-7915256-B2 | Triazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS NV (BE) | 2011-03-29 | — | — | US | disclosed |
| US-20100298300-A1 | TRIAZOLOPYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE & INFLAMMATORY DISEASES | ANDREWS MARTIN JAMES INGLIS | 2010-11-25 | — | — | US | disclosed |
| US-20100298300-A1 | TRIAZOLOPYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE & INFLAMMATORY DISEASES | ANDREWS MARTIN JAMES INGLIS | 2010-11-25 | — | — | US | disclosed |
| US-7501411-B2 | Triazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS, NV (BE) | 2009-03-10 | — | — | US | disclosed |
| US-7501411-B2 | Triazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS, NV (BE) | 2009-03-10 | — | — | US | disclosed |
| US-20080090818-A1 | Triazolopyrazine compounds useful for the treatment of degenerative & inflammatory diseases | GALAPAGOS NV (BE) | 2008-04-17 | — | — | US | disclosed |
| US-20080090818-A1 | Triazolopyrazine compounds useful for the treatment of degenerative & inflammatory diseases | GALAPAGOS NV (BE) | 2008-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178067-A1 | TRIAZOLOPYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | PTGES, IL1B, PTGER1 | MAPKAPK5 5/4885PTK6 1486/4885LCK 2250/4885 |
| US-20100298300-A1 | TRIAZOLOPYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE & INFLAMMATORY DISEASES | P2RX5, P2RX3, IL1B | MAPKAPK5 18/4885PTK6 1659/4885LCK 2336/4885 |
| US-20080090818-A1 | Triazolopyrazine compounds useful for the treatment of degenerative & inflammatory diseases | P2RX5, P2RX3, IL1B | MAPKAPK5 18/4885PTK6 1659/4885LCK 2336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.